Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care.

National Collaborating Centre for Chronic Conditions (UK).

London: Royal College of Physicians (UK); 2006.

2.

Clinical predictive factors of subthalamic stimulation in Parkinson's disease.

Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, Arnulf I, Pidoux B, Dormont D, Cornu P, Agid Y.

Brain. 2002 Mar;125(Pt 3):575-83.

3.

Treatment of Parkinson's disease: problems with a progressing disease.

Rinne UK.

J Neural Transm. 1981;51(1-2):161-74.

PMID:
7264627
4.

The medical treatment of Parkinson disease from James Parkinson to George Cotzias.

Fahn S.

Mov Disord. 2015 Jan;30(1):4-18. doi: 10.1002/mds.26102. Epub 2014 Dec 9. Review.

PMID:
25491387
5.

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.

Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.

Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561. Epub 2013 Jul 12.

PMID:
23853029
6.

Unmet medical needs in Parkinson's disease.

Koller WC, Tse W.

Neurology. 2004 Jan 13;62(1 Suppl 1):S1-8. Review.

PMID:
14718675
7.
8.

[Variance in effects of subthalamic nucleus stimulation].

Okiyama R, Yokochi F, Taniguchi M, Takahashi H, Hasegawa N, Hamada I.

No To Shinkei. 2002 Oct;54(10):883-8. Japanese.

PMID:
12476577
9.

[Rating scale and functional prognosis of Parkinson's disease].

Nakano I, Fujimoto K.

Nihon Rinsho. 2000 Oct;58(10):2132-8. Review. Japanese.

PMID:
11068460
10.

Helicobacter pylori eradication for Parkinson's disease.

Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y.

Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008453. doi: 10.1002/14651858.CD008453.pub2. Review.

PMID:
22071847
11.

Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.

Lees AJ, Tolosa E, Olanow CW.

Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8. Review.

PMID:
25488030
12.

Bromocriptine and the clinical spectrum of Parkinson's disease.

Riopelle RJ.

Can J Neurol Sci. 1987 Aug;14(3 Suppl):455-9.

PMID:
3676920
13.

Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Deleu D, Hanssens Y, Northway MG.

Drugs Aging. 2004;21(11):687-709. Review.

PMID:
15323576
14.

Ropinirole: a review of its use in the management of Parkinson's disease.

Matheson AJ, Spencer CM.

Drugs. 2000 Jul;60(1):115-37. Review.

PMID:
10929932
15.

Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

Stowe R, Ives N, Clarke CE, Deane K; van Hilten, Wheatley K, Gray R, Handley K, Furmston A.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166. doi: 10.1002/14651858.CD007166.pub2. Review.

PMID:
20614454
16.

The evolution and origin of motor complications in Parkinson's disease.

Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW.

Neurology. 2000;55(11 Suppl 4):S13-20; discussion S21-3. Review.

PMID:
11147505
17.
18.

Amantadine for dyskinesia in Parkinson's disease.

Crosby NJ, Deane KH, Clarke CE.

Cochrane Database Syst Rev. 2003;(2):CD003467. Review.

PMID:
12804468
19.

Cabergoline for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2001;(1):CD001518. Review.

PMID:
11279720
20.

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

Deane KH, Spieker S, Clarke CE.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004554. Review.

PMID:
15495119
Items per page

Supplemental Content

Write to the Help Desk